Corrigendum to “Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects” [Pharmacol. Res. 60 (2009) 159–169] (Ibuprofen–arginine generates nitric oxide and has enhanced anti-inflammatory effects (2009) 60(4) (221–228), (S1043661809001674), (10.1016/j.phrs.2009.06.002));Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects

Pharmacological Research

Volumn 60, Issue 4, 2009, Pages 221-228

  De Palma, Clara ^a   Di Paola, Rosanna ^c   Perrotta, Cristiana ^a   Mazzon, Emanuela ^c   Cattaneo, Dario ^a   Trabucchi, Emilio ^b   Cuzzocrea, Salvatore ^c   Clementi, Emilio ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Apoptosis; Arginine; Arthritis; Ibuprofen; Nitric oxide; Salification

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IBUPROFEN; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; CARTILAGE CELL; CELL PROTECTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PAW EDEMA; PLEIOTROPY; PRIORITY JOURNAL;

EID: 69249221334     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2023.107002     Document Type: Erratum

References (51)

1. Busson M. Update on ibuprofen: review article. J Int Med Res 14 (1986) 53-62
2. Davies E.F., and Avery G.S. Ibuprofen: a review of its pharmacological properties and therapeutic efficacy in rheumatic disorders. Drugs 2 (1971) 416-446
3. Whittle B.J. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17 (2003) 301-313
4. Moore N., Noblet C., and Breemeersch C. Focus on the safety of ibuprofen at the analgesic-antipyretic dose. Therapie 51 (1996) 458-463
5. Davies N.M. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 34 (1998) 101-154
6. Sadaba B., Campanero M.A., Munoz-Juarez M.J., Gil-Aldea I., Garcia-Quetglas E., Esteras A., et al. A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers. Eur J Clin Pharmacol 62 (2006) 849-854
7. Fini A., Zecchi C., and Tartarini A. Dissolution profiles of NSAID carboxylic acids and their salts with different counter ions. Pharm Acta Helv 60 (1985) 58-62
8. Ceppi Monti N., Gazzaniga A., Gianesello V., Stroppolo F., and Lodola E. Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. Arzneimittelforschung 42 (1992) 556-559
9. De Nadai C., Sestili P., Cantoni O., Lievremont J.P., Sciorati C., Barsacchi R., et al. Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. Proc Natl Acad Sci USA 97 (2000) 5480-5485
10. Bulotta S., Barsacchi R., Rotiroti D., Borgese N., and Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J Biol Chem 276 (2001) 6529-6536
11. Lievremont J.P., Sciorati C., Morandi E., Paolucci C., Bunone G., Della Valle G., et al. The p75(ntr)-induced apoptotic program develops through a ceramide-caspase pathway negatively regulated by nitric oxide. J Biol Chem 274 (1999) 15466-15472
12. Brunelli S., Rovere-Querini P., Sciorati C., Manfredi A.A., and Clementi E. Nitric oxide: emerging concepts about its use in cell-based therapies. Expert Opin Investig Drugs 16 (2007) 33-43
13. De Palma C., Falcone S., Panzeri C., Radice S., Bassi M.T., and Clementi E. Endothelial nitric oxide synthase overexpression by neuronal cells in neurodegeneration: a link between inflammation and neuroprotection. J Neurochem 106 (2008) 193-204
14. Dijkstra G., van Goor H., Jansen P.L., and Moshage H. Targeting nitric oxide in the gastrointestinal tract. Curr Opin Investig Drugs 5 (2004) 529-536
15. Bersimbaev R.I., Yugai Y.E., Hanson P.J., and Tzoy I.G. Effect of nitric oxide on apoptotic activity in the rat gastrointestinal tract. Eur J Pharmacol 423 (2001) 9-16
16. Franco L., and Doria D. Nitric oxide enhances prostaglandin production in ethanol-induced gastric mucosal injury in rats. Eur J Pharmacol 348 (1998) 247-256
17. Konturek J.W., Fischer H., Gromotka P.M., Konturek S.J., and Domschke W. Endogenous nitric oxide in the regulation of gastric secretory and motor activity in humans. Aliment Pharmacol Ther 13 (1999) 1683-1691
18. Ichikawa T., Kusakabe T., Gono Y., Shikama N., Hiruma H., Kawakami T., et al. Nitric oxide synthase activity in rat gastric mucosa contributes to mucin synthesis elicited by calcitonin gene-related peptide. Biomed Res 27 (2006) 117-124
19. Mollace V., Muscoli C., Masini E., Cuzzocrea S., and Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57 (2005) 217-252
20. Mitchell J.A., Ali F., Bailey L., Moreno L., and Harrington L.S. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 93 (2008) 141-147
21. Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn't the stomach digest itself?. Physiol Rev 88 (2008) 1547-1565
22. Gyires K. Gastric mucosal protection: from prostaglandins to gene-therapy. Curr Med Chem 12 (2005) 203-215
23. Duda D.G., Fukumura D., and Jain R.K. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 10 (2004) 143-145
24. Wallace J.L., and Vong L. NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Curr Opin Investig Drugs 9 (2008) 1151-1156
25. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2 (2001) 907-916
26. Paolucci C., Rovere P., De Nadai C., Manfredi A.A., and Clementi E. Nitric oxide inhibits the tumor necrosis factor alpha-regulated endocytosis of human dendritic cells in a cyclic GMP-dependent way. J Biol Chem 275 (2000) 19638-19644
27. Sciorati C., Nistico G., Meldolesi J., and Clementi E. Nitric oxide effects on cell growth: GMP-dependent stimulation of the ap-1 transcription complex and cyclic GMP-independent slowing of cell cycling. Br J Pharmacol 122 (1997) 687-697
28. Closs E.I., Simon A., Vekony N., and Rotmann A. Plasma membrane transporters for arginine. J Nutr 134 (2004) 2752S-2759S [discussion 2765S-2767S]
29. Doherty G.A., and Murray F.E. Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?. Expert Opin Ther Targets 13 (2009) 209-218
30. Parfitt J.R., and Driman D.K. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 38 (2007) 527-536
31. Gallego-Sandin S., Novalbos J., Rosado A., Gisbert J.P., Galvez-Mugica M.A., Garcia A.G., et al. Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions. Dig Dis Sci 49 (2004) 1538-1544
32. Gisbert J.P., Abad-Santos F., Novalbos J., Khorrami S., Gallego-Sandin S., Rosado A., et al. Comparison of gastric endoscopic lesions and tolerability to ibuprofen and ibuprofen-arginate in healthy subjects. J Clin Gastroenterol 39 (2005) 834-835
33. Liu L., and Stamler J.S. No: an inhibitor of cell death. Cell Death Differ 6 (1999) 937-942
34. Beltran B., Mathur A., Duchen M.R., Erusalimsky J.D., and Moncada S. The effect of nitric oxide on cell respiration: a key to understanding its role in cell survival or death. Proc Natl Acad Sci USA 97 (2000) 14602-14607
35. Takuma K., Phuagphong P., Lee E., Mori K., Baba A., and Matsuda T. Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J Biol Chem 276 (2001) 48093-48099
36. Clementi E., Borgese N., and Meldolesi J. Interactions between nitric oxide and sphingolipids and the potential consequences in physiology and pathology. Trends Pharmacol Sci 24 (2003) 518-523
37. Mowat A. Connective tissue diseases. Clin Haematol 1 (1972) 573-594
38. Roe R.L. Drug therapy in rheumatic diseases. Med Clin North Am 61 (1977) 405-418
39. Mullane K.M., Westlin W., and Kraemer R. Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. Ann N Y Acad Sci 524 (1988) 103-121
40. Clancy R.M., and Abramson S.B. Nitric oxide: a novel mediator of inflammation. Proc Soc Exp Biol Med 210 (1995) 93-101
41. Hughes M.N. Chemistry of nitric oxide and related species. Methods Enzymol 436 (2008) 3-19
42. Stefanovic-Racic M., Meyers K., Meschter C., Coffey J.W., Hoffman R.A., and Evans C.H. Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. J Rheumatol 22 (1995) 1922-1928
43. Tanaka S., Matsui T., Murakami T., Ishizuka T., Sugiura M., Kawashima K., et al. Immunological abnormality associated with the augmented nitric oxide synthesis in adjuvant-induced arthritis. Int J Immunopharmacol 20 (1998) 71-84
44. Alderton W.K., Cooper C.E., and Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J 357 (2001) 593-615
45. Persichini T., Cantoni O., Suzuki H., and Colasanti M. Cross-talk between constitutive and inducible no synthase: an update. Antioxid Redox Signal 8 (2006) 949-954
46. Xu L., Han C., Lim K., and Wu T. Activation of cytosolic phospholipase a2alpha through nitric oxide-induced s-nitrosylation. Involvement of inducible nitric-oxide synthase and cyclooxygenase-2. J Biol Chem 283 (2008) 3077-3087
47. Fiorucci S., and Antonelli E. NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 5 (2006) 121-131
48. Goligorsky M.S. Immune system in renal injury and repair: burning the candle from both ends?. Pharmacol Res 58 (2008) 122-128
49. Hristov M., and Weber C. Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res 58 (2008) 148-151
50. Schafer M., and Werner S. Oxidative stress in normal and impaired wound repair. Pharmacol Res 58 (2008) 165-171
51. Qvist P., Bay-Jensen A.C., Christiansen C., Dam E.B., Pastoureau P., and Karsdal M.A. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?. Pharmacol Res 58 (2008) 1-7